查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1912609

按產品類型、材質、應用、最終用戶和分銷管道分類的黏性注射器市場—2026-2032年全球預測

Bonded Syringe Market by Product Type, Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，黏合注射器市場價值將達到 8.3527 億美元，到 2026 年將成長至 8.9628 億美元，到 2032 年將達到 14.8027 億美元，複合年成長率為 8.51%。

關鍵市場統計數據
基準年 2025 8.3527億美元
預計年份：2026年 8.9628億美元
預測年份 2032 1,480,270,000 美元
複合年成長率 (%) 8.51%

對黏合注射器市場進行全面概述，重點關注安全性、製造創新、監管要求和供應鏈韌性。

黏合注射器產業正處於臨床需求、安全法規和製造創新三者交匯發展的階段。對安全注射技術的日益重視，以及疫苗接種計劃和慢性病管理的不斷擴展，促使人們更加關注能夠提高無菌性、給藥精度和使用者安全性的注射器設計特性。同時，材料科學和組裝流程的進步正在改變成本結構，並催生出新型預灌封和安全型注射器，以滿足醫護人員和患者的需求。

以安全為導向的產品演進、數位化可追溯性和地理分散式製造如何重塑競爭格局和品質預期

組合注射器的市場格局正經歷著變革性的轉變，這主要得益於技術、臨床和政策的共同發展。首先，隨著醫療系統將減少針刺傷和用藥錯誤列為優先事項，安全設計和預灌封包裝已從小眾應用領域走向主流採購清單。聚合物工程和玻璃加工技術的逐步進步推動了這一轉變，這些進步實現了安全密封、精準給藥以及與針頭安全功能的整合。

檢驗了截至2025年美國關稅對注射器價值鏈籌資策略、成本動態和供應鏈韌性的累積影響。

美國在2025年前實施的關稅和貿易政策調整，對保稅注射器供應鏈產生了顯著的累積影響，波及採購決策、成本結構和供應商策略。關稅導致的投入成本上漲，使得玻璃和塑膠組件的到岸成本上升，迫使買家重新評估長期契約，並推動更透明的成本轉嫁機制。為此，許多製造商正在加快供應商多元化和本土化生產，以降低進口關稅和物流波動帶來的風險。

可操作的細分資訊揭示了產品類型、應用、終端用戶通路、通路和材料選擇如何共同驅動差異化需求和策略。

細分分析揭示了因產品形式、臨床用途、終端用戶環境、通路和材料選擇而異的細微機會和限制因素。依產品類型分類，市場包括一次性注射器、傳統注射器、預灌封注射器和安全注射器，其中安全注射器可進一步細分為玻璃和塑膠材質。這些差異至關重要，因為玻璃和聚合物預灌封注射器在器械設計、滅菌途徑以及與特定治療方法的兼容性方面存在顯著差異。

區域趨勢分析：美洲、歐洲、中東和非洲以及亞太地區的趨勢對產能決策、合規策略和分銷模式的影響

區域趨勢顯著影響絕緣注射器市場的製造地選擇、監管合規負擔和分銷複雜性。在美洲，採購趨勢強調韌性、監管可追溯性以及透過強大的低溫運輸和庫存管理系統來支持大規模疫苗宣傳活動的能力。該地區的公共和私人買家通常要求供應商進行風險評估、提供品質認證並保證可靠的前置作業時間，這影響著製造商如何優先考慮區域生產能力。

競爭對手和供應商生態系統洞察凸顯了無菌生產規模、監管準備和創新管道如何決定競爭優勢。

主要企業與新興企業之間的競爭動態集中在預填充劑型的大規模無菌生產能力、法規遵循、安全性和產品創新。老牌製造商致力於提升密封完整性和自動化組裝流程等漸進式技術改進，而新參與企業則專注於透過增強安全性和採用永續性材料等方式在細分市場中脫穎而出。醫療設備製造商與製藥公司在預填充給藥系統領域的合作日益增多，反映出生物製藥和自我給藥療法的日益普及。

產業領導者可以採取切實可行的營運、監管和商業性措施，以增強供應鏈韌性、加速創新並滿足買家預期

產業領導者應在業務營運、產品策略和商業性合作等方面採取果斷行動，抓住近期機會並建立永續的韌性。首先，應優先考慮雙源採購和區域產能策略，以降低關稅風險並縮短前置作業時間，同時協商合約條款，以分擔供應鏈各環節的風險。其次，應投資模組化生產線和檢驗的自動化技術，以實現玻璃和塑膠預灌裝規格之間的快速切換，並能靈活應對需求波動。

我們嚴謹的混合方法研究途徑結合了高階主管訪談、監管分析、專利和臨床文獻審查以及情境檢驗，以確保獲得可靠的見解。

本分析結合了第一手和第二手研究資料，以確保其可靠性、檢驗和實用性。第一手研究包括對採購主管、醫院供應鏈經理、契約製造主管和監管事務專家的訪談，以了解當前的業務重點和決策促進因素。第二手研究涵蓋了監管指導文件、關於製造最佳實踐的白皮書、醫療設備創新專利申請以及探討安全性和可用性設計考慮的同行評審臨床文獻。

總之，綜合分析表明，營運柔軟性、嚴格的監管合規性和以客戶為中心的創新對於確保在注射器生態系統中保持永續的主導地位至關重要。

總之，黏合注射器產業正處於一個轉折點，產品安全性、供應鏈韌性和監管審查三者相互交織，重新定義了競爭優勢。那些積極平衡生產柔軟性與嚴格品管，並提供可追溯性和以服務為導向的商業模式的製造商和供應商，將獲得永續的競爭優勢。採購經理應預期，市場將繼續關注區域生產能力、檢驗的多源採購策略以及價值鏈風險共用的合約機制。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型分類的黏合劑注射器市場

  • 自動丟棄注射器
  • 普通注射器
  • 預灌封注射器

第9章 黏合劑注射器市場：依材料分類

  • 玻璃
  • 塑膠

第10章 黏合劑注射器市場：依應用領域分類

  • 藥物輸送
  • 胰島素給藥
  • 疫苗接種
    • 成人疫苗接種
    • 兒童疫苗接種

第11章 以最終用戶分類的黏合劑注射器市場

  • 門診手術中心
  • 診所
  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 按分銷管道分類的黏合劑注射器市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 黏性注射器市場：按地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的黏合劑注射器市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國黏性注射器市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國黏合劑注射器市場

第17章 中國醫用黏膠注射器市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Credence MedSystems, Inc.
  • DMC Medical Limited
  • Gerresheimer AG
  • Henke-Sass, Wolf GmbH
  • Hindustan Syringes & Medical Devices Ltd
  • Nipro Corporation
  • SCHOTT AG
  • Smiths Medical, Inc.
  • Terumo Corporation
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-AE420CB13A5B

The Bonded Syringe Market was valued at USD 835.27 million in 2025 and is projected to grow to USD 896.28 million in 2026, with a CAGR of 8.51%, reaching USD 1,480.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 835.27 million
Estimated Year [2026] USD 896.28 million
Forecast Year [2032] USD 1,480.27 million
CAGR (%) 8.51%

A comprehensive orientation to the bonded syringe landscape emphasizing safety, manufacturing innovation, regulatory expectations, and supply chain resilience

The bonded syringe sector is evolving at the intersection of clinical demand, safety regulation, and manufacturing innovation. Increasing emphasis on safe injection practices, combined with expanded vaccination programs and chronic disease management, has intensified attention on syringe design features that improve sterility, dosing accuracy, and user safety. Concurrently, material science advances and automation in assembly are reshaping cost structures and enabling new prefillable and safety-enabled formats that respond to clinician and patient needs.

Regulatory agencies worldwide have tightened expectations around device safety and supply transparency, creating higher compliance thresholds for manufacturing and post-market surveillance. These pressures are prompting forward-looking manufacturers to integrate traceability features, enhanced sterilization validation, and design-for-assembly approaches early in development. At the same time, healthcare providers are demanding more resilient supply chains and product consistency, particularly for high-volume items used across vaccination, insulin administration, and hospital settings.

As a result, stakeholders across the value chain-from raw material suppliers and component manufacturers to distributors and large institutional purchasers-are rethinking partnerships, vertical integration options, and inventory strategies. This introduction frames the broader forces that shape competitive positioning, R&D prioritization, and procurement strategy within the bonded syringe ecosystem, establishing context for the deeper analysis that follows.

How safety-driven product evolution, digitized traceability, and regionalized manufacturing are reshaping competitive dynamics and quality expectations

The bonded syringe landscape is undergoing transformative shifts driven by converging technological, clinical, and policy developments. Firstly, safety-engineered designs and prefillable formats have migrated from niche applications to mainstream procurement lists as healthcare systems prioritize reducing needlestick injuries and medication errors. This transition is supported by incremental advances in polymer engineering and glass processing that enable reliable sealing, precise dosing, and integration with needle safety mechanisms.

Secondly, digitization is emerging around product traceability and cold-chain monitoring, enabling better end-to-end visibility for high-value injectable therapies. Connected packaging concepts and serialization are increasingly discussed as part of risk mitigation and accountability frameworks, especially for mass vaccination campaigns. Thirdly, regulatory harmonization efforts in key jurisdictions are tightening requirements for post-market surveillance and component provenance, accelerating supplier audits and qualification rigor.

Finally, manufacturing models are shifting toward regionalization to reduce lead times and tariff exposure, while contract manufacturers invest in cleanroom automation and validated assembly lines capable of handling both glass and plastic prefillable formats. Together, these shifts are altering competitive dynamics, raising the bar for quality assurance, and creating opportunities for manufacturers that can combine robust regulatory compliance with flexible, cost-efficient production.

Examining the cumulative impact of United States tariff measures through 2025 on sourcing strategies, cost dynamics, and supply chain resilience across the syringe value chain

The imposition of tariffs and trade policy adjustments in the United States through 2025 has created a material cumulative effect across the bonded syringe supply chain, influencing sourcing decisions, cost structures, and supplier strategies. Tariff-driven input cost increases have translated into higher landed costs for both glass and plastic components, prompting buyers to re-evaluate long-term contracts and push for more transparent cost pass-through mechanisms. In response, many manufacturers have accelerated supplier diversification and onshoring initiatives to mitigate exposure to import levies and logistical volatility.

These shifts have also intensified emphasis on total landed cost analysis rather than unit price alone. Procurement teams now place greater weight on lead time reliability, inventory carrying costs, and the flexibility to scale production in response to demand surges. For some suppliers, the tariff environment has driven consolidation as smaller providers struggle with compressed margins and increased compliance costs; conversely, vertically integrated manufacturers have leveraged scale to absorb cost pressures while maintaining service levels.

Moreover, tariffs have encouraged investment in regional manufacturing capacity to serve large institutional buyers more directly, supporting faster replenishment cycles and tighter quality oversight. Consequently, strategic players are prioritizing resilience - reconfiguring supply networks, locking in secure raw material flows, and enhancing contractual terms to include contingency arrangements that reduce disruption risk.

Actionable segmentation intelligence revealing how product type, application, end-user channels, distribution pathways, and material choices together drive differentiated demand and strategy

Segmentation analysis reveals nuanced opportunities and constraints that vary by product form, clinical use, end-user setting, distribution pathway, and material selection. Based on Product Type, the market encompasses Auto-Disable Syringe, Conventional Syringe, Prefillable Syringe, and Safety Syringe, with the Prefillable Syringe further differentiated between Glass and Plastic formats. These distinctions matter because device design, sterilization pathways, and compatibility with specific therapies differ substantially between glass and polymer prefillable options.

Based on Application, the bonded syringe ecosystem serves Drug Delivery, Insulin Delivery, and Vaccination, with Vaccination subdivided into Adult Immunization and Pediatric Immunization, each segment presenting unique cold-chain and dosing considerations. Based on End User, demand streams originate from Ambulatory Surgical Centers, Clinics, Home Care, and Hospitals, where Hospitals further bifurcate into Private Hospitals and Public Hospitals, reflecting divergent procurement cycles, tendering behaviors, and margin sensitivities. Based on Distribution Channel, products flow through Direct Tender, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, while Online Pharmacies are further categorized into Direct To Consumer and Wholesale E-Channels, indicating growing e-commerce influence on last-mile delivery and consumer choice. Based on Material, the market is also studied across Glass and Plastic compositions, an axis that directly informs sterilization compatibility, environmental considerations, and breakage risk.

Taken together, these segmentation lenses highlight that competitive positioning must be multidimensional: product innovation should align with application clinical requirements, distribution strategies must reflect end-user purchasing behavior, and material decisions need to reconcile performance with cost and sustainability goals. Strategic portfolio decisions informed by this segmentation will favor modular platforms and adaptable supply arrangements that can be tuned to the distinct needs of each channel and clinical use case.

Regional intelligence showing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape capacity decisions, compliance tactics, and distribution models

Regional dynamics significantly influence manufacturing location choices, regulatory compliance burdens, and distribution complexity across the bonded syringe landscape. In the Americas, procurement trends emphasize resilience, regulatory traceability, and the ability to support large-scale vaccination campaigns with robust cold-chain and inventory systems. Private and public institutional buyers in this region often require supplier risk assessments, quality certifications, and reliable lead times, shaping how manufacturers prioritize regional capacity.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with variable procurement capabilities across countries, producing a patchwork of requirements that suppliers must navigate through localized compliance strategies and flexible distribution networks. This region values sustainability credentials and increasingly rigorous post-market surveillance mechanisms, which inform product design choices and materials selection.

In Asia-Pacific, high-volume production capacity and rapidly growing healthcare access create both competitive manufacturing advantages and intense local demand. Manufacturers in this region are investing in automation and quality management to meet export standards while also servicing robust domestic vaccination and insulin delivery needs. Across all three regions, the balance between centralized manufacturing efficiency and local responsiveness continues to drive strategic investment decisions, supplier partnerships, and distribution models that align with regional policy, clinical practice, and procurement behavior.

Competitor and supplier ecosystem insights highlighting how sterile manufacturing scale, regulatory readiness, and innovation pipelines determine competitive advantage

Competitive dynamics among leading and emerging companies center on capabilities in high-volume sterile manufacturing, regulatory compliance, and product innovation for safety and prefilled formats. Established manufacturers are pursuing incremental engineering improvements, such as enhanced seal integrity and automated assembly processes, while new entrants focus on niche differentiation through safety-enabled features or sustainability-focused materials. Partnerships between device makers and pharmaceutical firms for prefilled drug delivery systems are growing, reflecting the increasing prevalence of biologics and self-administered therapies.

Market leaders are investing in expanded sterilization capacity, serialization, and digital quality systems to provide customers with audit-ready supply chains and predictable batch release timelines. Meanwhile, contract manufacturing organizations that can flex production across glass and polymer prefillable formats are seeing demand from brands seeking to reduce capital expenditure and accelerate time to market. Supplier ecosystems are also evolving to prioritize validated raw material sources and multi-sourcing strategies to reduce single-point-of-failure risks.

Collectively, these company-level trends indicate that competitive advantage will accrue to organizations that combine certified cleanroom infrastructure, robust regulatory affairs teams, and agile product development pipelines capable of responding to shifts in application mix, such as the rising share of self-administered chronic therapies.

Practical operational, regulatory, and commercial actions industry leaders can implement to strengthen supply resilience, accelerate innovation, and align with buyer expectations

Industry leaders should act decisively across operations, product strategy, and commercial engagement to capture near-term opportunities and build durable resilience. First, prioritize dual-sourcing and regional capacity strategies to reduce tariff exposure and compress lead times, while negotiating contractual clauses that share risk across the supply chain. Second, invest in modular manufacturing lines and validated automation that permit rapid conversion between glass and plastic prefillable formats and enable scalable responses to demand variability.

Third, deepen collaboration with healthcare purchasers by offering value-added services such as end-to-end traceability data, clinician training modules on safety devices, and inventory-as-a-service models that reduce hospital stockouts and overall system waste. Fourth, enhance regulatory and quality systems to expedite customer audits and support cross-border market entry, with particular attention to serialization and post-market surveillance capabilities. Fifth, integrate sustainability metrics into product roadmaps and supplier evaluations to meet evolving buyer expectations and regulatory pressures.

Finally, align commercial models with digital distribution trends by developing e-commerce readiness for direct-to-consumer channels and building analytics capabilities to track demand signals. Combined, these actions will strengthen competitive positioning while reducing exposure to trade and supply disruptions.

A rigorous mixed-methods research approach combining executive interviews, regulatory analysis, patent and clinical literature review, and scenario validation to ensure dependable insights

This analysis synthesizes primary and secondary research streams designed to ensure reliability, triangulation, and practical relevance. Primary inputs include interviews with procurement leaders, hospital supply chain managers, contract manufacturing executives, and regulatory affairs specialists to capture current operational priorities and decision drivers. Secondary inputs encompass regulatory guidance documents, manufacturing best-practice white papers, patent filings for device innovations, and peer-reviewed clinical literature that informs safety and usability design considerations.

Data validation involved cross-referencing qualitative insights with observable industry behavior such as announced capacity investments, procurement tender terms, and supplier certification records. Where possible, historical shipment and trade patterns were examined to understand sourcing trends and the logistics impact of tariff changes. Analysts also applied scenario analysis to test the sensitivity of supplier networks to disruptive events and policy shifts, producing actionable implications for procurement and manufacturing strategies.

Throughout, methodological rigor was maintained by documenting interview protocols, coding qualitative responses for thematic consistency, and applying conservative interpretation rules to avoid overstating trends. This multi-layered approach ensures the findings are grounded in practitioner experience and corroborated by verifiable industry indicators.

Concluding synthesis emphasizing the imperative for operational flexibility, regulatory rigor, and customer-centric innovation to secure durable advantage in the syringe ecosystem

In conclusion, the bonded syringe landscape is at an inflection point where safety-driven product evolution, supply chain resilience, and regulatory scrutiny converge to redefine competitive success. Manufacturers and suppliers that proactively align manufacturing flexibility with stringent quality management, and that offer traceability and service-oriented commercial models, will find durable advantage. Procurement leaders should expect continued emphasis on regional capacity, validated multi-sourcing, and contractual mechanisms that share risks across the value chain.

The combined pressures of material selection, application-specific requirements, and distribution channel evolution mean that strategic portfolios must be nimble enough to support both institutionally procured volumes and growing direct-to-consumer pathways. By prioritizing investments in automation, serialization, and regulatory readiness, stakeholders can reduce vulnerability to trade shocks and accelerate time to market for differentiated prefillable and safety-enabled offerings. The path forward rewards those who balance operational rigor with customer-centric innovation, enabling more reliable, safer injection delivery for diverse clinical settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bonded Syringe Market, by Product Type

  • 8.1. Auto-Disable Syringe
  • 8.2. Conventional Syringe
  • 8.3. Prefillable Syringe

9. Bonded Syringe Market, by Material

  • 9.1. Glass
  • 9.2. Plastic

10. Bonded Syringe Market, by Application

  • 10.1. Drug Delivery
  • 10.2. Insulin Delivery
  • 10.3. Vaccination
    • 10.3.1. Adult Immunization
    • 10.3.2. Pediatric Immunization

11. Bonded Syringe Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Bonded Syringe Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bonded Syringe Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bonded Syringe Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bonded Syringe Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bonded Syringe Market

17. China Bonded Syringe Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun Melsungen AG
  • 18.6. Becton, Dickinson and Company
  • 18.7. Credence MedSystems, Inc.
  • 18.8. DMC Medical Limited
  • 18.9. Gerresheimer AG
  • 18.10. Henke-Sass, Wolf GmbH
  • 18.11. Hindustan Syringes & Medical Devices Ltd
  • 18.12. Nipro Corporation
  • 18.13. SCHOTT AG
  • 18.14. Smiths Medical, Inc.
  • 18.15. Terumo Corporation
  • 18.16. West Pharmaceutical Services, Inc.
  • 18.17. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BONDED SYRINGE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BONDED SYRINGE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BONDED SYRINGE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BONDED SYRINGE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BONDED SYRINGE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BONDED SYRINGE MARKET SIZE, BY AUTO-DISABLE SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BONDED SYRINGE MARKET SIZE, BY AUTO-DISABLE SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BONDED SYRINGE MARKET SIZE, BY AUTO-DISABLE SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BONDED SYRINGE MARKET SIZE, BY CONVENTIONAL SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BONDED SYRINGE MARKET SIZE, BY CONVENTIONAL SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BONDED SYRINGE MARKET SIZE, BY CONVENTIONAL SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BONDED SYRINGE MARKET SIZE, BY PREFILLABLE SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BONDED SYRINGE MARKET SIZE, BY PREFILLABLE SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BONDED SYRINGE MARKET SIZE, BY PREFILLABLE SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BONDED SYRINGE MARKET SIZE, BY GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BONDED SYRINGE MARKET SIZE, BY GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BONDED SYRINGE MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BONDED SYRINGE MARKET SIZE, BY PLASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BONDED SYRINGE MARKET SIZE, BY PLASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BONDED SYRINGE MARKET SIZE, BY PLASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BONDED SYRINGE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BONDED SYRINGE MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BONDED SYRINGE MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BONDED SYRINGE MARKET SIZE, BY INSULIN DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BONDED SYRINGE MARKET SIZE, BY INSULIN DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BONDED SYRINGE MARKET SIZE, BY INSULIN DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BONDED SYRINGE MARKET SIZE, BY ADULT IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BONDED SYRINGE MARKET SIZE, BY ADULT IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BONDED SYRINGE MARKET SIZE, BY ADULT IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BONDED SYRINGE MARKET SIZE, BY PEDIATRIC IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BONDED SYRINGE MARKET SIZE, BY PEDIATRIC IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BONDED SYRINGE MARKET SIZE, BY PEDIATRIC IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BONDED SYRINGE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BONDED SYRINGE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BONDED SYRINGE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BONDED SYRINGE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BONDED SYRINGE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BONDED SYRINGE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BONDED SYRINGE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BONDED SYRINGE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BONDED SYRINGE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BONDED SYRINGE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BONDED SYRINGE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BONDED SYRINGE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BONDED SYRINGE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BONDED SYRINGE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BONDED SYRINGE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BONDED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BONDED SYRINGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BONDED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)